News Release:
Summit Corporation plc
(‘Summit’ or ‘the Company’)
REPEAT DOSING OF SMT C1100 FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY MEETS ENDPOINTS IN PHASE 1 CLINICAL TRIAL
• New formulation delivers drug levels that are predicted to significantly increase utrophin…
ContinueAdded by PPMD on November 7, 2012 at 10:00am — No Comments
2018
2017
2016
2015
2014
2013
2012
2011
2010
© 2022 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service